Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer

NCT07845786 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT07845786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07845786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Single-Arm, Multicenter Trial of Zanzalintinib in Combination With Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer
Lead sponsor
Exelixis
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 15, 2026
Completion date
June 15, 2030
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

squamous non-small cell lung cancer (nsclc)